US Bancorp
VRDN icon

US Bancorp’s Viridian Therapeutics VRDN Stock Holding History

US Bancorp’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.49K Sell
190
-2,715
-93% -$43.7K ﹤0.01% 3749
2026
Q1 		$56.8K Buy
2,905
+286
+11% +$8.49K ﹤0.01% 2653
2025
Q4 		$81.5K Buy
2,619
+162
+7% +$4.44K ﹤0.01% 2479
2025
Q3 		$53K Buy
2,457
+463
+23% +$8.35K ﹤0.01% 2655
2025
Q2 		$27.9K Buy
1,994
+504
+34% +$6.84K ﹤0.01% 3045
2025
Q1 		$20.1K Buy
1,490
+592
+66% +$10.1K ﹤0.01% 3168
2024
Q4 		$17.2K Buy
+898
New +$19.5K ﹤0.01% 3222
2023
Q4 		– Sell
-37
Closed -$568 – 4162
2023
Q3 		$568 Sell
37
-19,068
-100% -$364K ﹤0.01% 3830
2023
Q2 		$455K Sell
19,105
-1,390
-7% -$35.7K ﹤0.01% 1454
2023
Q1 		$521K Buy
20,495
+9,273
+83% +$297K ﹤0.01% 1382
2022
Q4 		$328K Buy
+11,222
New +$259K ﹤0.01% 1605
2019
Q1 		– Sell
-67
Closed -$3K – 3657
2018
Q4 		$3K Hold
67
– – ﹤0.01% 3348
2018
Q3 		$6K Hold
67
– – ﹤0.01% 3282
2018
Q2 		$6K Hold
67
– – ﹤0.01% 3292
2018
Q1 		$7K Hold
67
– – ﹤0.01% 3258
2017
Q4 		$10K Buy
+67
New +$8.54K ﹤0.01% 3147

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

US Bancorp's VRDN Position: Q2 2026 in Review

US Bancorp reduced its Viridian Therapeutics (VRDN) stake by 93% in Q2 2026, selling an estimated $43.7K and leaving 190 shares worth $3.49K. The position accounts for ﹤0.01% of the portfolio, ranked #3749.

US Bancorp first reported a position in VRDN in Q4 2017 and has held it in 16 quarters since. The position peaked at $521K in Q1 2023. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • US Bancorp held 190 shares of Viridian Therapeutics worth $3.49K as of Q2 2026.
  • US Bancorp sold 2,715 Viridian Therapeutics shares in Q2 2026, an estimated $43.7K.
  • Viridian Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3749 holding.
  • US Bancorp first reported a position in Viridian Therapeutics in Q4 2017 and has held it in 16 quarters since.
  • US Bancorp's Viridian Therapeutics position peaked at $521K in Q1 2023.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.